Cargando…

Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study

INTRODUCTION: Deep venous thrombosis with subsequent pulmonary embolism or post-thrombotic syndrome is a feared complication in the intensive care unit. Therefore, routine prophylactic anticoagulation is widely recommended. Aside from unfractionated heparin, low molecular weight heparins, such as ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jochberger, Stefan, Mayr, Viktoria, Luckner, Günter, Fries, Dietmar R, Mayr, Andreas J, Friesenecker, Barbara E, Lorenz, Ingo, Hasibeder, Walter R, Ulmer, Hanno, Schobersberger, Wolfgang, Dünser, Martin W
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297619/ https://www.ncbi.nlm.nih.gov/pubmed/16277716 http://dx.doi.org/10.1186/cc3792

Ejemplares similares

Causes of death and determinants of outcome in critically ill patients
por: Mayr, Viktoria D, et al.
Publicado: (2006)

Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome
por: Luckner, Günter, et al.
Publicado: (2006)

Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression
por: Schmittinger, Christian A, et al.
Publicado: (2008)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement
por: Bramlage, Peter, et al.
Publicado: (2012)

Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial
por: Melzer, Nima, et al.
Publicado: (2014)

Vasopressor stays vasopressor and inotrope stays inotrope!
por: Luckner, Günter, et al.
Publicado: (2008)

Arteriolar vasoconstrictive response: comparing the effects of arginine vasopressin and norepinephrine
por: Friesenecker, Barbara E, et al.
Publicado: (2006)

Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry
por: Grünewald, Martin, et al.
Publicado: (2021)

Effects of three different resuscitation regimens on jejunal tissue oxygen supply after hemorrhagic shock
por: Pajk, W, et al.
Publicado: (2002)

Is the degree of multiple organ dysfunction related to severity of capillary leakage?
por: Knotzer, H, et al.
Publicado: (2002)

Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in a young adult
por: Philipponnet, C., et al.
Publicado: (2020)

Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition
por: Meah, Mohammed N., et al.
Publicado: (2020)

Withholding and withdrawing therapy at the intensive care units of the University Hospital of Innsbruck, Austria
por: Fries, D, et al.
Publicado: (2001)

Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition
por: Mavromanoli, Anna C., et al.
Publicado: (2021)

A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study
por: Dorsch, Oliver, et al.
Publicado: (2012)

Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review
por: Deville, Clemence, et al.
Publicado: (2016)

Necrotizing fasciitis of the lower extremity caused by perforated sigmoid diverticulitis—a case report
por: Kröpfl, Veronika, et al.
Publicado: (2018)

Antithrombotic Prophylaxis in the Middle East
por: Arnaout, Samir, et al.
Publicado: (2011)

Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes
por: Hornung, Paul, et al.
Publicado: (2020)

The Influence of Environmental Hypoxia on Hemostasis—A Systematic Review
por: Treml, Benedikt, et al.
Publicado: (2022)

Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen
por: Tsiailanis, Antonios D., et al.
Publicado: (2023)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Right drug, wrong dosage: insights from the PAVE-AF antithrombotic study in older patients with atrial fibrillation
por: Tzeis, Stylianos, et al.
Publicado: (2020)

An experiment with VM/XA share
por: Pope, B G
Publicado: (1990)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
por: Hohaus, Stefan, et al.
Publicado: (2020)

Marker-aided Incorporation of Xa38, a Novel Bacterial Blight Resistance Gene, in PB1121 and Comparison of its Resistance Spectrum with xa13 + Xa21
por: Ellur, Ranjith K., et al.
Publicado: (2016)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Litlin xa ninin = Alabanzas para todos los santos /
Publicado: (1993)

Influence of Acute Normobaric Hypoxia on Hemostasis in Volunteers with and without Acute Mountain Sickness
por: Schaber, Marc, et al.
Publicado: (2015)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Clinical Scenarios for Discordant Anti-Xa
por: Vera-Aguilera, Jesus, et al.
Publicado: (2016)

Roles of factor Xa beyond coagulation
por: Ruf, Wolfram
Publicado: (2021)

Vasopressin in vasodilatory shock: ensure organ blood flow, but take care of the heart!
por: Dünser, Martin W, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_c62gml3s78e8l4dfrlt0lkogm0